[New insights and perspectives in the management of dyslipidemia]

Area of Science:

• Cardiovascular Pharmacology
• Lipid Metabolism Research
• Pharmacological Interventions

Context:

• Coronary heart disease (CHD) risk is significantly influenced by lipid profiles.
• Epidemiologic studies confirm high-density lipoprotein cholesterol (HDL-C) as a key inverse predictor of CHD.
• Patients with type 2 diabetes and metabolic syndrome often present with unfavorable lipid profiles, necessitating targeted therapies.

Purpose:

• To review the efficacy of current and emerging lipid-lowering drugs.
• To explore pharmacological strategies for increasing HDL-C levels.
• To address the unmet need for effective HDL-C-raising therapies in specific patient populations.

Summary:

• Rosuvastatin demonstrates high efficacy in lowering LDL-C, though clinical benefit data is pending.
• Ezetimibe, by inhibiting cholesterol absorption, shows promise when co-administered with statins.
• Niacin is effective for raising HDL-C but poses tolerability challenges, including glucose dysregulation and hepatotoxicity.
• CETP inhibitors show potential for increasing HDL-C, but their clinical utility requires further validation.

Impact:

• Highlights the importance of achieving target LDL-C levels for high-risk individuals.
• Emphasizes the therapeutic potential of novel agents for managing dyslipidemia.
• Underscores the need for improved HDL-C-raising strategies to mitigate cardiovascular risk.